P3+ Intervention Phase
tiistai 4. elokuuta 2020 päivittänyt: Robert Bednarczyk, Emory University
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
This study will address vaccine uptake both for pregnant women and for their children, through 20 months of age, to test the hypothesis that exposure to the P3+ intervention package will increase the likelihood a pregnant woman gets herself vaccinated against influenza and pertussis before delivery and get her child vaccinated on time.
This study builds off of a prior intervention, developed by Emory, at the practice, provider, and patient levels (P3) to develop, implement and evaluate an enhanced intervention (P3+) to improve vaccination uptake among pregnant women, and later, their children.
Tutkimuksen yleiskatsaus
Tila
Valmis
Ehdot
Yksityiskohtainen kuvaus
This study will address vaccine uptake both for pregnant women and for their children, through 20 months of age, to test the hypothesis that exposure to the P3+ intervention package will increase the likelihood a pregnant woman gets herself vaccinated against influenza and pertussis before delivery and get her child vaccinated on time.
This study uses a multi-level factorial design which randomizes at both the practice and the patient level. Obstetric practices in Georgia and Colorado will be randomized to be either an intervention practice or a control practice. The women recruited in the practices and enrolled in the study will be randomly assigned to the intervention arm or the control arm.
Women randomized to the intervention arm will complete a computer-based questionnaire (administered via iPad with a preloaded study app) which asks for their basic demographic and contact information and asks questions about their vaccine knowledge, attitudes, and beliefs. Immediately following the questionnaire, participants will receive the individual level intervention (videos providing information on vaccines) on the same iPad. In order to best answer their questions and not provide information beyond the scope of what the study participants need or want, the videos provided to each participant will be selected based on responses to the survey questions. There are 6 videos: one discusses the dangers of the diseases prevented by vaccines, and the others address specific vaccine concerns (concerns include vaccine ingredients, children receiving simultaneous vaccines (multiple vaccines at one time), and the safety of receiving the tdap or flu vaccine during pregnancy). If the participant does not have any concerns, they will only see the video about dangers of vaccine preventable diseases. Participants expressing concerns in the survey will receive up to two videos addressing those concerns, based on an order of priority determined by the study researchers.
Women randomized to the control arm will also complete a computer-based questionnaire which includes their personal information and vaccine knowledge, attitudes, and beliefs questions but will then continue to receive usual prenatal care rather than view informational videos.
All enrolled women complete two follow-up surveys when their children are 30 days and 18 months of age.
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
2200
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
Colorado
-
Aurora, Colorado, Yhdysvallat, 80045
- CU Center for Midwifery
-
Aurora, Colorado, Yhdysvallat, 80045
- CU Maternal and Fetal Medicine Clinic
-
Aurora, Colorado, Yhdysvallat, 80045
- University Nurse Midwives
-
Boulder, Colorado, Yhdysvallat, 80303
- Boulder Women's Care
-
Denver, Colorado, Yhdysvallat, 80218
- St. Joe's Midwives
-
Denver, Colorado, Yhdysvallat, 80220
- Partners in Women's Health at Rose
-
Denver, Colorado, Yhdysvallat, 80220
- Rocky Mountain OBGYN
-
Edwards, Colorado, Yhdysvallat, 81632
- Colorado Mountain Medical
-
Englewood, Colorado, Yhdysvallat, 80113
- Bella Natural Women's Care
-
Golden, Colorado, Yhdysvallat, 80401
- Associates in Women's Health
-
Thornton, Colorado, Yhdysvallat, 80229
- Women's Health Group Thornton
-
-
Georgia
-
Alpharetta, Georgia, Yhdysvallat, 30005
- Atlanta Women's Specialists
-
Alpharetta, Georgia, Yhdysvallat, 30005
- Roswell Ob/Gyn
-
Athens, Georgia, Yhdysvallat, 30606
- Athens Midwifery
-
Athens, Georgia, Yhdysvallat, 30606
- Athens Ob-Gyn
-
Athens, Georgia, Yhdysvallat, 30606
- Women's Healthcare Associates of Athens
-
Atlanta, Georgia, Yhdysvallat, 30322
- Emory Clinic
-
Atlanta, Georgia, Yhdysvallat, 30342
- Riverbend OB/GYN and Counseling
-
Cumming, Georgia, Yhdysvallat, 30041
- Peachtree Women's Clinic
-
Duluth, Georgia, Yhdysvallat, 30096
- Comprehensive Women's OB/GYN
-
Dunwoody, Georgia, Yhdysvallat, 30338
- Dunwoody Ob-Gyn
-
Lilburn, Georgia, Yhdysvallat, 30047
- Atlanta Gynecology & Obstetrics
-
Tyrone, Georgia, Yhdysvallat, 30290
- Women's Medical Center
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
18 vuotta - 50 vuotta (Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Joo
Sukupuolet, jotka voivat opiskella
Nainen
Kuvaus
Inclusion Criteria:
- Have not previously participated in this study
- Currently pregnant
- Up to 26 weeks gestational age
- Able to understand and communicate in English
Exclusion Criteria:
- Have received pertussis vaccine during the current pregnancy
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Terveyspalvelututkimus
- Jako: Satunnaistettu
- Inventiomalli: Tehtävätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Muut: Control Site + Control Patient
The obstetric practice site is randomized to be a control site and the patient is randomized to the control group.
|
Control sites will continue with their standard practice regarding discussing vaccines with their patients.
Muut nimet:
Participants randomized the control arm will complete a computer-based questionnaire, on an iPad with a preloaded app.
The questionnaire asks about vaccine knowledge, attitudes, and beliefs and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby.
The questionnaire includes questions requiring a "yes" or "no" response, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), questions to capture the vaccines participants plan to get for themselves and their children, and open-ended questions.
|
|
Kokeellinen: Control Site + Intervention Patient
The obstetric practice site is randomized to be a control site and the patient is randomized to receive the intervention.
|
Control sites will continue with their standard practice regarding discussing vaccines with their patients.
Muut nimet:
Participants randomized to the intervention arm will complete a computer-based questionnaire on an iPad with a preloaded app, prior to watching informational videos covering topics on maternal and childhood vaccines.
The questionnaire asks about vaccine knowledge, attitudes, beliefs, and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby.
The questions require "yes" or "no" responses, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), and open-ended responses.
After watching at least one informational video, the participant completes a questionnaire asking about the perceived usefulness of the app, degree of agreement with the vaccine information presented in the video, and ways to make the app more useful to participants.
|
|
Kokeellinen: Intervention Site + Control Patient
The obstetric practice site is randomized to be an intervention site and the patient is randomized to the control group.
|
Participants randomized the control arm will complete a computer-based questionnaire, on an iPad with a preloaded app.
The questionnaire asks about vaccine knowledge, attitudes, and beliefs and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby.
The questionnaire includes questions requiring a "yes" or "no" response, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), questions to capture the vaccines participants plan to get for themselves and their children, and open-ended questions.
Intervention Sites will each assign a Vaccine Champion and will have Assessment, Feedback, Incentives, and eXchange (AFIX) visits.
AFIX is a quality improvement program to raise immunization coverage levels, reduce missed opportunities to vaccinate, and improve standards of practices at the provider level.
A Continuing Medical Education (CME) module will be given to all providers, covering the recommended maternal vaccinations and how to talk to patients about vaccines.
Intervention sites will have access to written materials covering all recommended maternal and infant vaccinations, the diseases they prevent, potential adverse reactions and common patient questions with talking points and references for each topic.
Muut nimet:
|
|
Kokeellinen: Intervention Site + Intervention Patient
The obstetric practice site is randomized to be an intervention site and the patient is randomized to receive the intervention.
|
Participants randomized to the intervention arm will complete a computer-based questionnaire on an iPad with a preloaded app, prior to watching informational videos covering topics on maternal and childhood vaccines.
The questionnaire asks about vaccine knowledge, attitudes, beliefs, and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby.
The questions require "yes" or "no" responses, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), and open-ended responses.
After watching at least one informational video, the participant completes a questionnaire asking about the perceived usefulness of the app, degree of agreement with the vaccine information presented in the video, and ways to make the app more useful to participants.
Intervention Sites will each assign a Vaccine Champion and will have Assessment, Feedback, Incentives, and eXchange (AFIX) visits.
AFIX is a quality improvement program to raise immunization coverage levels, reduce missed opportunities to vaccinate, and improve standards of practices at the provider level.
A Continuing Medical Education (CME) module will be given to all providers, covering the recommended maternal vaccinations and how to talk to patients about vaccines.
Intervention sites will have access to written materials covering all recommended maternal and infant vaccinations, the diseases they prevent, potential adverse reactions and common patient questions with talking points and references for each topic.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of women receiving influenza vaccination
Aikaikkuna: Up to 34 weeks
|
Whether or not the participant chose to receive the flu vaccine during pregnancy (between the baseline visit and birth of infant) will be compared between study arms
|
Up to 34 weeks
|
|
Number of women receiving pertussis vaccination
Aikaikkuna: Up to 34 weeks
|
Whether or not the participant chose to receive the pertussis vaccine during pregnancy (between the baseline visit and birth of infant) will be compared between study arms
|
Up to 34 weeks
|
|
Timely childhood vaccinations
Aikaikkuna: 20 months
|
Childhood vaccination will be assessed as timely uptake of childhood vaccines by calculating average days under-vaccinated.
The total number of days under-vaccinated will be divided by the number of vaccines a child should have received, according to the Advisory Committee on Immunization Practices (ACIP) schedule, to give the average number of days under-vaccinated across all recommended vaccines.
This can range from 0 to 415 days in the first 20 months of life.
The average number of days under-vaccinated will be modeled as a continuous variable, and the distribution of days under-vaccinated will be evaluated, in total and by vaccine where possible, to identify specific patterns of interest for follow-up.
|
20 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Changes in maternal vaccine knowledge
Aikaikkuna: Up to 106 weeks (baseline visit until 18 months post delivery)
|
Maternal vaccine knowledge will be collected by the app surveys at different time periods, including before receiving the patient-level intervention, immediately after receiving the intervention, and 30 days and 18 months after the birth of the child.
The survey questions assessing these outcomes will most often be measured on a Likert scale.
Changes in these outcomes over time will be compared between mothers in the different study arms.
|
Up to 106 weeks (baseline visit until 18 months post delivery)
|
|
Changes in maternal vaccine attitudes
Aikaikkuna: Up to 106 weeks (baseline visit until 18 months post delivery)
|
Maternal vaccine attitudes will be collected by the app surveys at different time periods, including before receiving the patient-level intervention, immediately after receiving the intervention, and 30 days and 18 months after the birth of the child.
The survey questions assessing these outcomes will most often be measured on a Likert scale.
Changes in these outcomes over time will be compared between mothers in the different study arms.
|
Up to 106 weeks (baseline visit until 18 months post delivery)
|
|
Changes in maternal vaccine beliefs
Aikaikkuna: Up to 106 weeks (baseline visit until 18 months post delivery)
|
Maternal vaccine beliefs will be collected by the app surveys at different time periods, including before receiving the patient-level intervention, immediately after receiving the intervention, and 30 days and 18 months after the birth of the child.
The survey questions assessing these outcomes will most often be measured on a Likert scale.
Changes in these outcomes over time will be compared between mothers in the different study arms.
|
Up to 106 weeks (baseline visit until 18 months post delivery)
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Daniel Salmon, PhD, MPH, Johns Hopkins Bloomberg School of Public Health
Julkaisuja ja hyödyllisiä linkkejä
Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Maanantai 12. kesäkuuta 2017
Ensisijainen valmistuminen (Todellinen)
Maanantai 6. heinäkuuta 2020
Opintojen valmistuminen (Todellinen)
Maanantai 6. heinäkuuta 2020
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Torstai 8. syyskuuta 2016
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Torstai 8. syyskuuta 2016
Ensimmäinen Lähetetty (Arvio)
Tiistai 13. syyskuuta 2016
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Keskiviikko 5. elokuuta 2020
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Tiistai 4. elokuuta 2020
Viimeksi vahvistettu
Lauantai 1. elokuuta 2020
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
- IRB00090267
- 5R01AI110482-02 (Yhdysvaltain NIH-apuraha/sopimus)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .